Interpace Biosciences, Inc. (OTCID:IDXG)

Interpace Biosciences, Inc. (OTC:IDXG) announced preliminary full year and fourth quarter 2024 results:

• Q4 and FY Test volume increase 21% and 17% year-over-year

• Q4 and FY Volume, Revenue, and Profitability at all-time record levels

“Q4 continued the Company’s trend of double-digit year-over-year volume and revenue growth fueled by the full suite of Interpace testing services. Physician demand for ThyGeNEXT® + ThyraMIR®v2, our Company’s unique mutational- and microRNA-based assay for indeterminate thyroid nodules was exceptionally high and a very strong driver of the Company’s profitability. stated Tom Burnell, President and CEO. Burnell added, “the Company completed a strong year financially in 2024 which has set the stage to continue to execute its strategy of growth in 2025. The Company understands the uncertainty surrounding PancraGEN® Medicare reimbursement going forward and, in the event of a non-coverage determination, has made plans to manage through this situation. Our Endo business unit is strong and profitable. It provides a solid foundation from which to continue our strong performance, should this situation occur.”

It appears that the record level of profitability could at least translate to EPS of at least $0.40. We need to take a deeper dive into the June financials to be sure there were no one time items. We also plan to take a closer look at the capital structure to be sure the current 4.4 million share count is accurate. 

Two things to consider on capital structure:

• Conversion of preferred stock would take fully diluted count to 28 million shares (conversion price is at $2)

• In our December open forum, Maj talked about the company and the likelihood of an equity raise. 

See our recent coverage on IDXG for our breakdown of the PancaGEN Medicare/Medicaid coverage determination.

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States